Effect of CTAP101 Capsules on Serum Calcium, Plasma Intact Parathyroid Hormone and Vitamin D Metabolites in Patients With Advanced Breast or Prostate Carcinomas With Metastases to Bone and Receiving Ongoing Therapy With Denosumab or Zoledronic Acid

Trial Profile

Effect of CTAP101 Capsules on Serum Calcium, Plasma Intact Parathyroid Hormone and Vitamin D Metabolites in Patients With Advanced Breast or Prostate Carcinomas With Metastases to Bone and Receiving Ongoing Therapy With Denosumab or Zoledronic Acid

Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Apr 2017

At a glance

  • Drugs Calcifediol (Primary)
  • Indications Bone cancer; Breast cancer; Hyperparathyroidism; Prostate cancer
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors OPKO Health
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Apr 2017 Planned End Date changed from 1 Feb 2017 to 1 Dec 2018.
    • 11 Apr 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top